Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, stemming from material misstatements in financial statements related to its subsidiary, Lugano Holdings, Inc. [1][3][4] Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2] - Investors have until July 8, 2025, to request to be appointed to lead the case [2] Group 2: Financial Misstatements - Compass admitted that its fiscal 2022-2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable for Lugano [3] - On May 7, 2025, Compass announced that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, leading to a stock price decline of approximately 62%, from $17.25 to $6.55 per share [4] - On June 25, 2025, Compass further advised that investors should not rely on its fiscal 2022 and 2023 financial statements amid the ongoing investigation [5] Group 3: Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs in this case [7] - The firm operates on a contingency fee basis, meaning there are no upfront costs for shareholders [6]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility redeterminations and its financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID but resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to the Medicaid redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 3: Stock Performance and Financial Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following Novo Nordisk's announcement on June 23, 2025, to terminate its partnership with Hims & Hers due to these deceptive practices, Hims & Hers' stock price dropped by over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for misleading investors regarding its dividend policy following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Financial Developments - Following the Dermavant acquisition, Organon increased its debt but assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [3]. - This announcement led to a decline in Organon's stock price by $3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, alleging that the company made false and misleading statements regarding its business model and growth prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Petco's pandemic-related growth was unsustainable and that the company's business model, which focuses on premium pet food, was overstated [5]. - Defendants allegedly downplayed the severity of issues affecting Petco's business and overstated its ability to achieve sustainable, profitable growth [5]. - Investors are encouraged to join the class action, with no out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].

Core Viewpoint - A class action securities lawsuit has been filed against Reddit, Inc. for alleged securities fraud affecting investors between October 29, 2024, and May 20, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the impact of changes in Google Search's algorithm, which led to a significant reduction in traffic to Reddit [2]. - It is claimed that the defendants were aware that users were finding answers directly on Google Search, leading to a decrease in visits to Reddit, contrary to their public statements about user rates and advertising revenues [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 18, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleadingly positive statements while concealing material adverse facts about its growth potential and ability to meet demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].